Welcome to our dedicated page for ONCOLYTICS BIOTECH SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oncolytics Biotech filings document a clinical-stage oncology company developing pelareorep and reporting material events through Form 8-K disclosures. Recent filings cover pelareorep study updates in metastatic colorectal cancer and squamous cell anal carcinoma, FDA-related development communications, translational data presented from GOBLET and AWARE-1, and incorporation of certain exhibits into a Form F-3 registration statement.
The company's regulatory record also documents capital-structure matters, including Nasdaq-listed ONCY common stock and an open-market sale agreement, as well as corporate-status changes tied to its completed continuance and domestication from Canadian jurisdictions to Nevada. These filings describe governance approvals, registered securities, financing arrangements, and oncology development disclosures for the issuer.
Oncolytics Biotech Inc. established an at-the-market program to sell up to $50.0 million of common shares through BTIG, LLC, which may be sold from time to time under a shelf registration on Form F-3 and an accompanying prospectus supplement. The company will pay a 3.0% commission on gross proceeds, and either party may terminate the agreement on 10 days’ notice.
Any net proceeds will be used to fund clinical development of pelareorep, related R&D, operating costs, working capital and general corporate purposes. The company states that no shares may be offered or sold in Canada.
Separately, the company filed a Form F-4 for a planned domestication from Alberta, Canada to Nevada, intended to be effective when it ceases to be a foreign private issuer on January 1, 2026 or as soon as practicable thereafter. The company cites perceived benefits of Nevada’s corporate law but notes there is no assurance the domestication will occur on the expected timeline or deliver the anticipated benefits.
Oncolytics Biotech Inc. filed a Form F-4 and sent a combined management information circular and prospectus seeking shareholder approvals to change its jurisdiction in two steps: first a continuance from Alberta to British Columbia, then a domestication to Nevada, and to adopt the 2025 Incentive Award Plan. Each step is subject to the required shareholder vote and the Board’s discretion to proceed.
If completed, each outstanding common share will continue as one share through the Continuance and become one share of Oncolytics Nevada common stock without any surrender or exchange. The company’s shares will continue to trade on Nasdaq under ONCY. Dissent rights are available under Alberta and British Columbia law as described, and the filing includes risk factors and tax considerations related to the redomiciliation.
Oncolytics Biotech Inc. (ONCY) launched an at-the-market offering of up to $50,000,000 in common shares through BTIG, LLC, which may act as sales agent or principal. Sales may be made from time to time in transactions deemed an “at the market offering” under Rule 415.
The Agent will receive a 3.0% commission on gross proceeds. On October 16, 2025, ONCY last traded at $1.17 per share on Nasdaq. The company intends to use net proceeds to fund clinical development of pelareorep, associated R&D, operating costs, working capital and general corporate purposes.
As context, common shares outstanding were 97,407,903 as of June 30, 2025. Assuming sales at $1.17, the company illustrates up to 42,735,042 shares sold, with up to 140,142,945 shares outstanding immediately after the offering. Under that assumption, the filing shows an immediate dilution of $0.79 per share to new investors at the assumed price.